Skip to content
Search

Latest Stories

India’s Aditya Birla Forms Joint Venture With US Based Varde

US-based investment company Varde Partners Inc. and India’s financial services provider Aditya Birla Capital Limited (ABCL) have formed a joint venture to invest in stressed and distressed assets in India.

As information on the joint venture came out, shares of ABCL on benchmark Bombay Stock Exchange (BSE) climbed as much as 4.8 per cent on Thursday (23), the biggest intraday gain recorded after July 26.


An upward movement in ABCL shares came amid a 0.1 per cent slump in the broader S&P BSE Sensex. ABCL shares opened at Rs 140.70 and touched an intra-day high of Rs 144.80 to close at Rs 14.05 recording an uptick of 4.23 per cent on Thursday.

According to the deal, Minneapolis based Varde will acquire a 50 per cent share in ABCL’s asset reconstruction business for £ 10.63 million, the Indian company said in a filing without specifying the actual size of the planned investment to be made by the duo. However, sources claimed that the joint venture aims to put as much as 0.77 billion pounds into stressed and distressed assets in India over the next three years.

As per the plan set up by both parties, “operating through a joint platform, both parties will evaluate investments across sectors, focusing on the acquisition, restructuring and resolution of the substantial supply of non-performing assets in India as well as special situations financings. Given the current landscape and further prospects in asset reconstruction in India, ABCL and Varde believe there is an attractive pipeline for strong capital deployment opportunities over the next several years,” said Varde in a release.

Ajay Srinivasan, Chief Executive of ABCL said, “The asset reconstruction company (ARC) business is a strong addition to the businesses we already have at ABCL. We see a large opportunity in the distressed space, especially in the mid-corporate segment. One of the things that we bring to the table as a group is that we understand how to run many businesses.”

“We are looking at leveraging this skill set as we enter this new business. Thus, our decision to enter into a joint venture with Varde Partners, who bring restructuring expertise to augment our core strength. The expertise and experience of both ABCL and Varde, makes this a strong combination to capitalise on the opportunity that India presents,” Ajay Srinivasan added.

“Varde currently manages about £ 10.75 billion globally, and has invested nearly £ 383.81m in India in the past five years across corporate stressed, distressed, special situations and lending assets. With regional headquarters established in Singapore in 2008, Varde expects to open its fifth Asia office in Mumbai later this year,” Varde said in a statement.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less